Nipocalimab authorised for adults with antibody-positive generalised myasthenia gravis

Deucrictibant shows rapid symptom relief and strong safety profile in RAPIDe-3 study

Funding supports phase 2 study of NeuroRestore ACD856 in patients

Company highlights safety and target engagement results for VNA-318 at CTAD meeting

Bimekizumab offers fresh option for patients with chronic conditions

hVIVO celebrates landmark deal highlighting its role in advancing influenza therapy

eXmoor Pharma and Royal Free London NHS Foundation Trust have announced a strategic collaboration to create a seamless […]

Foundation’s test to be used in Oxford-led blood biomarker trial

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease

First PD-1 inhibitor plus ADC regimens for cisplatin-ineligible patients